View ValuationVaxart 将来の成長Future 基準チェック /06Vaxartの収益と利益はそれぞれ年間65.4%と28.2%減少すると予測されていますが、EPS は年間25.8% 減少すると予測されています。主要情報-28.2%収益成長率-25.82%EPS成長率Biotechs 収益成長23.7%収益成長率-65.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日01 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 07Vaxart Reports Topline 12-Month Safety Data from the 400-Participant Sentinel Safety Cohort of the Phase 2B Clinical Trial of Its Oral Pill Covid-19 VaccineVaxart reported topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events (AEs) were reported in either arm of the study. Data from the complete study, comprising the 400 dosed participants in the sentinel safety cohort and approximately 5,000 dosed participants in the main cohort, are currently anticipated in 2027. Participants in the main cohort received vaccines targeting the KP.2 viral strain prevalent at the time cohort dosing was initiated. Key topline 12-month results from the 400-participant sentinel safety cohort (201 oral vaccinees and 199 mRNA vaccinees) include: No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher AEs were reported in either the oral pill vaccine or mRNA arms of the trial. The most common AEs in participants receiving the oral pill vaccine were malaise/fatigue (20.9%), headache (18.9%) and anorexia (10.0%). Fewer than 10% of participants experienced any other AE. The most common AEs in participants receiving the mRNA vaccine were injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%), myalgia/muscle pain (33.2%), and headache (28.6%). Arthralgia, chills, anorexia, nausea, diarrhea, and induration/swelling at the injection site were experienced by between 10-15% of participants. Fewer than 10% of participants experienced any other AE. With respect to the efficacy measure of symptomatic COVID, 33 participants in Vaxart’s oral pill vaccine arm and 30 participants in the injectable mRNA vaccine arm had symptomatic disease. Asymptomatic COVID cases were reported in 12 participants in the Vaxart oral pill arm and 12 in the mRNA vaccine arm. It should be noted that this 400-participant sentinel safety cohort was not powered to determine comparative efficacy between the two arms. Topline data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, are anticipated in 2027. The main cohort is designed and powered to support the planned statistical comparison of safety and relative efficacy outcomes between the two arms. Funding for this award was received under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart’s project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $344.8 million. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.お知らせ • Jul 02Vaxart, Inc. Announces Board and Committee ChangesVaxart, Inc. announced a resolution to the proxy contest in connection with the Company's 2026 Annual Meeting of Stockholders. Vaxart, Inc. initiated a search for an additional independent director to be conducted within 90 days of the conclusion of the 2026 Annual Meeting. Pursuant to a cooperation agreement between the Company and stockholders Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD, Patrice Raffy, Marc Eustace Pereira and Third Quarter Nominees Pty Ltd., the Company will work with the Stockholder Group to identify a mutually agreeable candidate to be appointed to the Board. The Stockholder Group agreed under the cooperation agreement to withdraw the director nominations of Mr. Houle, Dr. Silverberg and Dr. Wallace in connection with the 2026 Annual Meeting. The cooperation agreement additionally provided for the formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, Board committee refreshment, including the selection of new chairs for the Nominating and Governance and Compensation Committees, the adoption of director stock ownership and resignation policies, as well as certain customary standstill, voting, engagement and other provisions.お知らせ • Jun 25Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine TrialVaxart entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology International, to support continuation of the Company’s ongoing Phase 2b COVID-19 oral pill vaccine candidate and advance the next phase of data analysis. Overall funding available for the trial is now approximately $345 million, a decrease of approximately $116 million from its prior modification, following an approximately 50% reduction in participants enrolled in the trial as the result of a BARDA partial termination ordered on August 5, 2025. Per the Company’s contract with Advanced Technology International, the total funding amount available to Vaxart represents an estimate of the costs that will be incurred in the study as it is currently contemplated. The latest modification allows for the release of approximately $29 million for completion of the trial and exploratory analyses to further evaluate safety and efficacy, enabling Vaxart to conduct deeper analytics from the trial data set. Vaxart intends to report 12-month data from the 400-participant Sentinel Cohort in the coming weeks and 12-month data from the 5,085-participant main cohort in the first half of 2027. Funding for this award was received under Project NextGen, an initiative led by BARDA and the National Institute of Allergy and Infectious Diseases to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Other Transaction Number: 75A50123D00005. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus.お知らせ • Jun 23Daniel P. Houle Issues an Investor PresentationOn June 22, 2026, Daniel P. Houle issued an investor presentation titled “A Case for Change at Vaxart”, and urged the shareholders of Vaxart, Inc to vote for his nominees; Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace.お知らせ • Jun 10Daniel Houle Issues Letter to Shareholders of VaxartOn June 10, 2026, Daniel P. Houle issued letter to shareholders of Vaxart, Inc., seeking support to vote FOR accountability, transparency, and stockholder value by electing Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace. In addition, Daniel P. Houle stating that the stockholders believe the Company possesses a unique technology platform, but stockholder value has remained compromised due to disappointing performance, declining market value, and insufficient engagement, and they call for restoring confidence, increasing transparency, improving communication, and ensuring stockholder interests are central to decision-making. Further, Daniel P. Houle stating that the nominees bring governance, healthcare, clinical, and operational expertise to strengthen oversight and accountability while supporting strategic partnerships, improved communication of the VAAST platform, rebuilding trust, and establishing committees to enhance regulatory oversight and stockholder relations. Furthermore, Daniel P. Houle in the letter concludes that the campaign is about improvement, accountability, and maximizing stockholder value, urging stockholders to vote for transparency, accountability, and stockholder representation.お知らせ • Jun 09Daniel P. Houle Provides Information to Shareholders of VaxartOn June 6, 2026, Daniel P. Houle posted a message on Stocktwits. Daniel P. Houle reposted the message on Stocktwits on June 7, 2026, and he anticipates reposting it daily on Stocktwits through the date of Vaxart, Inc.’s annual meeting.お知らせ • May 20Vaxart, Inc., Annual General Meeting, Jul 16, 2026Vaxart, Inc., Annual General Meeting, Jul 16, 2026.お知らせ • May 01Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026Vaxart, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Apr 24Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of DirectorsVaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. In February 2026, he joined Altay Therapeutics as CEO and Board Director, directing the advancement of the company’s pipeline of oral transcription factor therapies. He most recently served as the President and CEO of Oncternal Therapeutics, Inc., where he oversaw the clinical development of a diverse pipeline of first-in-class oncology assets. He also brings vaccine development expertise from his previous role as President of Bavarian Nordic, Inc., where he oversaw the development of cancer, infectious disease, and bioterrorism vaccines. Additionally, Dr. Breitmeyer held senior clinical leadership roles at Eli Lilly and Company and Cadence Pharmaceuticals, where he managed the transition of multiple candidates through the clinical and regulatory process toward successful commercial launch. His board experience includes previous director roles at Zogenix, Inc. and Otonomy, Inc., where he served on Audit and Compensation Committees. Previously, he held the position of President at Bavarian Nordic, Inc. and served as Executive Vice President and Chief Medical Officer at Cadence Pharmaceuticals. Dr. Breitmeyer also served as Vice President of Biotechnology at Eli Lilly and Company, where he was responsible for the corporate biotechnology pipeline. Earlier in his career, he held senior leadership roles at Applied Molecular Evolution and Serono Laboratories, where he led the development of therapies resulting in FDA approvals for Rebif® and Serostim®. Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine. He completed postdoctoral fellowships at Harvard Medical School and the Dana-Farber Cancer Institute, where he also served as a clinical instructor.お知らせ • Apr 18Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLCVaxart, Inc. announces that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC to issue common stock for gross proceeds of $25,000,000 on April 16, 2026. The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/ or Rule 506(b) of Regulation D thereunder.業績と収益の成長予測BST:NB11 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028N/A-338-301-301112/31/2027N/A-284-235-235112/31/202635611612512513/31/2026256371515N/A12/31/20252371688N/A9/30/2025148-51-30-30N/A6/30/202581-57-37-37N/A3/31/202547-58-34-33N/A12/31/202429-67-45-45N/A9/30/202417-72-51-51N/A6/30/202414-76-62-62N/A3/31/20249-82-68-67N/A12/31/20237-82-72-70N/A9/30/20234-89-92-86N/A6/30/20232-101-93-86N/A3/31/20231-108-104-94N/A12/31/20220-108-104-95N/A9/30/20220-105-88-81N/A6/30/20220-93-87-81N/A3/31/20220-80-74-68N/A12/31/20211-70-65-60N/A9/30/20211-64-60-55N/A6/30/20211-54-54-50N/A3/31/20212-47-39-37N/A12/31/20204-32-25-24N/A9/30/20208-25-17-17N/A6/30/20208-22-12-12N/A3/31/20207-19-12-12N/A12/31/201910-19N/A-13N/A9/30/20198-17N/A-15N/A6/30/20198-18N/A-16N/A3/31/20198-22N/A-9N/A12/31/20184-18N/A-15N/A9/30/20183-15N/A-11N/A6/30/20184-12N/A-8N/A3/31/20185-7N/A-16N/A12/31/20176-12N/A-10N/A9/30/20179-16N/A-9N/A12/31/20168-19N/A-12N/A12/31/20150-22N/A-15N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NB11の収益は今後 3 年間で減少すると予測されています (年間-28.2% )。収益対市場: NB11の収益は今後 3 年間で減少すると予測されています (年間-28.2% )。高成長収益: NB11の収益は今後 3 年間で減少すると予測されています。収益対市場: NB11の収益は今後 3 年間で減少すると予想されています (年間-65.4% )。高い収益成長: NB11の収益は今後 3 年間で減少すると予測されています (年間-65.4% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NB11の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/27 05:57終値2026/03/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vaxart, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Mayank MamtaniB. Riley Securities, Inc.Roger SongJefferies LLCJay OlsonOppenheimer & Co. Inc.3 その他のアナリストを表示
お知らせ • Jul 07Vaxart Reports Topline 12-Month Safety Data from the 400-Participant Sentinel Safety Cohort of the Phase 2B Clinical Trial of Its Oral Pill Covid-19 VaccineVaxart reported topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events (AEs) were reported in either arm of the study. Data from the complete study, comprising the 400 dosed participants in the sentinel safety cohort and approximately 5,000 dosed participants in the main cohort, are currently anticipated in 2027. Participants in the main cohort received vaccines targeting the KP.2 viral strain prevalent at the time cohort dosing was initiated. Key topline 12-month results from the 400-participant sentinel safety cohort (201 oral vaccinees and 199 mRNA vaccinees) include: No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher AEs were reported in either the oral pill vaccine or mRNA arms of the trial. The most common AEs in participants receiving the oral pill vaccine were malaise/fatigue (20.9%), headache (18.9%) and anorexia (10.0%). Fewer than 10% of participants experienced any other AE. The most common AEs in participants receiving the mRNA vaccine were injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%), myalgia/muscle pain (33.2%), and headache (28.6%). Arthralgia, chills, anorexia, nausea, diarrhea, and induration/swelling at the injection site were experienced by between 10-15% of participants. Fewer than 10% of participants experienced any other AE. With respect to the efficacy measure of symptomatic COVID, 33 participants in Vaxart’s oral pill vaccine arm and 30 participants in the injectable mRNA vaccine arm had symptomatic disease. Asymptomatic COVID cases were reported in 12 participants in the Vaxart oral pill arm and 12 in the mRNA vaccine arm. It should be noted that this 400-participant sentinel safety cohort was not powered to determine comparative efficacy between the two arms. Topline data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, are anticipated in 2027. The main cohort is designed and powered to support the planned statistical comparison of safety and relative efficacy outcomes between the two arms. Funding for this award was received under Project NextGen, an initiative by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart’s project award through the Rapid Response Partnership Vehicle (RRPV) Consortium is valued at up to $344.8 million. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.
お知らせ • Jul 02Vaxart, Inc. Announces Board and Committee ChangesVaxart, Inc. announced a resolution to the proxy contest in connection with the Company's 2026 Annual Meeting of Stockholders. Vaxart, Inc. initiated a search for an additional independent director to be conducted within 90 days of the conclusion of the 2026 Annual Meeting. Pursuant to a cooperation agreement between the Company and stockholders Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD, Patrice Raffy, Marc Eustace Pereira and Third Quarter Nominees Pty Ltd., the Company will work with the Stockholder Group to identify a mutually agreeable candidate to be appointed to the Board. The Stockholder Group agreed under the cooperation agreement to withdraw the director nominations of Mr. Houle, Dr. Silverberg and Dr. Wallace in connection with the 2026 Annual Meeting. The cooperation agreement additionally provided for the formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, Board committee refreshment, including the selection of new chairs for the Nominating and Governance and Compensation Committees, the adoption of director stock ownership and resignation policies, as well as certain customary standstill, voting, engagement and other provisions.
お知らせ • Jun 25Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine TrialVaxart entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology International, to support continuation of the Company’s ongoing Phase 2b COVID-19 oral pill vaccine candidate and advance the next phase of data analysis. Overall funding available for the trial is now approximately $345 million, a decrease of approximately $116 million from its prior modification, following an approximately 50% reduction in participants enrolled in the trial as the result of a BARDA partial termination ordered on August 5, 2025. Per the Company’s contract with Advanced Technology International, the total funding amount available to Vaxart represents an estimate of the costs that will be incurred in the study as it is currently contemplated. The latest modification allows for the release of approximately $29 million for completion of the trial and exploratory analyses to further evaluate safety and efficacy, enabling Vaxart to conduct deeper analytics from the trial data set. Vaxart intends to report 12-month data from the 400-participant Sentinel Cohort in the coming weeks and 12-month data from the 5,085-participant main cohort in the first half of 2027. Funding for this award was received under Project NextGen, an initiative led by BARDA and the National Institute of Allergy and Infectious Diseases to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Other Transaction Number: 75A50123D00005. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus.
お知らせ • Jun 23Daniel P. Houle Issues an Investor PresentationOn June 22, 2026, Daniel P. Houle issued an investor presentation titled “A Case for Change at Vaxart”, and urged the shareholders of Vaxart, Inc to vote for his nominees; Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace.
お知らせ • Jun 10Daniel Houle Issues Letter to Shareholders of VaxartOn June 10, 2026, Daniel P. Houle issued letter to shareholders of Vaxart, Inc., seeking support to vote FOR accountability, transparency, and stockholder value by electing Daniel P. Houle, Mark Silverberg, and Matthew M. Wallace. In addition, Daniel P. Houle stating that the stockholders believe the Company possesses a unique technology platform, but stockholder value has remained compromised due to disappointing performance, declining market value, and insufficient engagement, and they call for restoring confidence, increasing transparency, improving communication, and ensuring stockholder interests are central to decision-making. Further, Daniel P. Houle stating that the nominees bring governance, healthcare, clinical, and operational expertise to strengthen oversight and accountability while supporting strategic partnerships, improved communication of the VAAST platform, rebuilding trust, and establishing committees to enhance regulatory oversight and stockholder relations. Furthermore, Daniel P. Houle in the letter concludes that the campaign is about improvement, accountability, and maximizing stockholder value, urging stockholders to vote for transparency, accountability, and stockholder representation.
お知らせ • Jun 09Daniel P. Houle Provides Information to Shareholders of VaxartOn June 6, 2026, Daniel P. Houle posted a message on Stocktwits. Daniel P. Houle reposted the message on Stocktwits on June 7, 2026, and he anticipates reposting it daily on Stocktwits through the date of Vaxart, Inc.’s annual meeting.
お知らせ • May 20Vaxart, Inc., Annual General Meeting, Jul 16, 2026Vaxart, Inc., Annual General Meeting, Jul 16, 2026.
お知らせ • May 01Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026Vaxart, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Apr 24Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of DirectorsVaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. In February 2026, he joined Altay Therapeutics as CEO and Board Director, directing the advancement of the company’s pipeline of oral transcription factor therapies. He most recently served as the President and CEO of Oncternal Therapeutics, Inc., where he oversaw the clinical development of a diverse pipeline of first-in-class oncology assets. He also brings vaccine development expertise from his previous role as President of Bavarian Nordic, Inc., where he oversaw the development of cancer, infectious disease, and bioterrorism vaccines. Additionally, Dr. Breitmeyer held senior clinical leadership roles at Eli Lilly and Company and Cadence Pharmaceuticals, where he managed the transition of multiple candidates through the clinical and regulatory process toward successful commercial launch. His board experience includes previous director roles at Zogenix, Inc. and Otonomy, Inc., where he served on Audit and Compensation Committees. Previously, he held the position of President at Bavarian Nordic, Inc. and served as Executive Vice President and Chief Medical Officer at Cadence Pharmaceuticals. Dr. Breitmeyer also served as Vice President of Biotechnology at Eli Lilly and Company, where he was responsible for the corporate biotechnology pipeline. Earlier in his career, he held senior leadership roles at Applied Molecular Evolution and Serono Laboratories, where he led the development of therapies resulting in FDA approvals for Rebif® and Serostim®. Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine. He completed postdoctoral fellowships at Harvard Medical School and the Dana-Farber Cancer Institute, where he also served as a clinical instructor.
お知らせ • Apr 18Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLCVaxart, Inc. announces that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC to issue common stock for gross proceeds of $25,000,000 on April 16, 2026. The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/ or Rule 506(b) of Regulation D thereunder.